CO6731132A2 - Comprimido de desintegración oral - Google Patents
Comprimido de desintegración oralInfo
- Publication number
- CO6731132A2 CO6731132A2 CO13176405A CO13176405A CO6731132A2 CO 6731132 A2 CO6731132 A2 CO 6731132A2 CO 13176405 A CO13176405 A CO 13176405A CO 13176405 A CO13176405 A CO 13176405A CO 6731132 A2 CO6731132 A2 CO 6731132A2
- Authority
- CO
- Colombia
- Prior art keywords
- fine granules
- active ingredient
- pharmaceutically active
- lansoprazole
- controlled release
- Prior art date
Links
- 239000008187 granular material Substances 0.000 abstract 8
- 239000004480 active ingredient Substances 0.000 abstract 6
- 238000013270 controlled release Methods 0.000 abstract 3
- 229920001577 copolymer Polymers 0.000 abstract 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 abstract 3
- 229960003174 lansoprazole Drugs 0.000 abstract 3
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 abstract 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 abstract 2
- 230000006835 compression Effects 0.000 abstract 2
- 238000007906 compression Methods 0.000 abstract 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 abstract 2
- 230000002035 prolonged effect Effects 0.000 abstract 2
- 229920000623 Cellulose acetate phthalate Polymers 0.000 abstract 1
- 239000001856 Ethyl cellulose Substances 0.000 abstract 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- -1 carboxymethyl ethyl Chemical group 0.000 abstract 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 239000011247 coating layer Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 229920001249 ethyl cellulose Polymers 0.000 abstract 1
- 235000019325 ethyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920000639 hydroxypropylmethylcellulose acetate succinate Polymers 0.000 abstract 1
- 229960003943 hypromellose Drugs 0.000 abstract 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 abstract 1
- 210000000214 mouth Anatomy 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061427384P | 2010-12-27 | 2010-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6731132A2 true CO6731132A2 (es) | 2013-08-15 |
Family
ID=45509604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO13176405A CO6731132A2 (es) | 2010-12-27 | 2013-07-25 | Comprimido de desintegración oral |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US20130273157A1 (https=) |
| EP (1) | EP2658530A2 (https=) |
| JP (1) | JP2014501224A (https=) |
| KR (1) | KR20140007364A (https=) |
| CN (1) | CN103402500A (https=) |
| AR (1) | AR084610A1 (https=) |
| AU (1) | AU2011350396A1 (https=) |
| BR (1) | BR112013014875A2 (https=) |
| CA (1) | CA2823166C (https=) |
| CL (1) | CL2013001793A1 (https=) |
| CO (1) | CO6731132A2 (https=) |
| CR (1) | CR20130327A (https=) |
| EA (1) | EA028217B1 (https=) |
| EC (1) | ECSP13012718A (https=) |
| MA (1) | MA34768B1 (https=) |
| MX (1) | MX2013007588A (https=) |
| PE (1) | PE20141115A1 (https=) |
| PH (1) | PH12013501391A1 (https=) |
| SG (2) | SG10201602311XA (https=) |
| TN (1) | TN2013000220A1 (https=) |
| TW (1) | TW201304823A (https=) |
| UY (1) | UY33841A (https=) |
| WO (1) | WO2012091153A2 (https=) |
| ZA (1) | ZA201304617B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI441658B (zh) | 2008-03-11 | 2014-06-21 | Takeda Pharmaceutical | 口腔崩解固體製劑 |
| ES2643403T3 (es) | 2011-12-28 | 2017-11-22 | Global Blood Therapeutics, Inc. | Compuestos de benzaldehído sustituidos y métodos para su uso en el aumento de la oxigenación tisular |
| HK1203412A1 (en) | 2011-12-28 | 2015-10-30 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| GB201303781D0 (en) | 2013-03-04 | 2013-04-17 | Gauthier Pierre Pascal | Oral timer device and method of using same |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| MX379235B (es) | 2013-03-15 | 2025-03-11 | Global Blood Therapeutics Inc | Compuestos y sus usos para modular la hemoglobina. |
| WO2014150258A1 (en) | 2013-03-15 | 2014-09-25 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| CN114181195A (zh) | 2014-02-07 | 2022-03-15 | 全球血液疗法股份有限公司 | 一种化合物的结晶多晶型物 |
| WO2016077832A2 (en) | 2014-11-14 | 2016-05-19 | Gemphire Therapeutics Inc. | PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS |
| WO2016174664A1 (en) | 2015-04-29 | 2016-11-03 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| SG11201804647TA (en) | 2015-12-04 | 2018-06-28 | Global Blood Therapeutics Inc | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| TW202332423A (zh) * | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| EP3612171A4 (en) | 2017-04-18 | 2020-10-21 | Gemphire Therapeutics Inc. | GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME |
| TW201906599A (zh) * | 2017-05-11 | 2019-02-16 | 美商珍費爾醫療公司 | 吉卡賓組成物及其使用方法 |
| BR112020000318A2 (pt) * | 2017-07-10 | 2020-07-14 | Takeda Pharmaceutical Company Limited | preparação |
| CN108576205B (zh) * | 2018-03-22 | 2022-01-04 | 湖北省农业科学院农产品加工与核农技术研究所 | 一种草莓联合干燥的处理方法 |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| JPH072761B2 (ja) | 1985-03-20 | 1995-01-18 | 不二パウダル株式会社 | 微結晶セルロ−ス球形顆粒及びその製造法 |
| JPS62277322A (ja) | 1986-02-13 | 1987-12-02 | Takeda Chem Ind Ltd | 安定化された腸溶性抗潰瘍固形組成物 |
| FR2679451B1 (fr) | 1991-07-22 | 1994-09-09 | Prographarm Laboratoires | Comprime multiparticulaire a delitement rapide. |
| DE69331839T2 (de) | 1992-01-29 | 2002-12-12 | Takeda Chemical Industries, Ltd. | Schnellösliche Tablette und ihre Herstellung |
| JP2919771B2 (ja) | 1995-04-17 | 1999-07-19 | 佐藤製薬株式会社 | 速溶解性錠剤の製造方法及び該製造方法により製造した速溶解性錠剤 |
| JPH0948726A (ja) | 1995-08-07 | 1997-02-18 | Tanabe Seiyaku Co Ltd | 口腔内速崩壊性製剤およびその製法 |
| JP3828648B2 (ja) | 1996-11-14 | 2006-10-04 | 武田薬品工業株式会社 | ２−（２−ピリジルメチルスルフィニル）ベンズイミダゾール系化合物の結晶およびその製造法 |
| TW385306B (en) | 1996-11-14 | 2000-03-21 | Takeda Chemical Industries Ltd | Method for producing crystals of benzimidazole derivatives |
| DK2263660T3 (en) | 1998-05-18 | 2018-01-02 | Takeda Pharmaceuticals Co | Orally disintegrating tablets. |
| ATE291418T1 (de) | 1998-07-28 | 2005-04-15 | Takeda Pharmaceutical | Leicht zerfallende feste zubereitung |
| TWI289557B (en) | 1999-06-17 | 2007-11-11 | Takeda Chemical Industries Ltd | A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| KR100775802B1 (ko) | 2000-04-28 | 2007-11-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 광학 활성 술폭시드 유도체의 제조 방법 |
| CN100562318C (zh) | 2000-05-15 | 2009-11-25 | 武田药品工业株式会社 | 晶体的制备方法 |
| ATE511508T1 (de) | 2000-12-01 | 2011-06-15 | Takeda Pharmaceutical | Verfahren zur kristallisation von (r)- oder (s)- lansoprazol |
| JP4493970B2 (ja) | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| US20050214372A1 (en) * | 2004-03-03 | 2005-09-29 | Simona Di Capua | Stable pharmaceutical composition comprising an acid labile drug |
| JP2009519334A (ja) * | 2005-12-20 | 2009-05-14 | テバ ファーマシューティカル インダストリーズ リミティド | ランソプラゾール経口崩壊錠剤 |
| US20070141151A1 (en) * | 2005-12-20 | 2007-06-21 | Silver David I | Lansoprazole orally disintegrating tablets |
| EP1837016A3 (en) * | 2006-03-08 | 2008-01-02 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical multiple-unit composition |
| US9486446B2 (en) * | 2006-12-28 | 2016-11-08 | Takeda Pharmaceutical Company Limited | Orally disintegrating solid preparation |
| TWI441658B (zh) * | 2008-03-11 | 2014-06-21 | Takeda Pharmaceutical | 口腔崩解固體製劑 |
| WO2010008569A1 (en) * | 2008-07-17 | 2010-01-21 | Barr Laboratories, Inc. | Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same |
-
2011
- 2011-12-26 BR BR112013014875A patent/BR112013014875A2/pt active Search and Examination
- 2011-12-26 KR KR1020137019795A patent/KR20140007364A/ko not_active Withdrawn
- 2011-12-26 JP JP2013529237A patent/JP2014501224A/ja active Pending
- 2011-12-26 SG SG10201602311XA patent/SG10201602311XA/en unknown
- 2011-12-26 EA EA201390981A patent/EA028217B1/ru not_active IP Right Cessation
- 2011-12-26 WO PCT/JP2011/080568 patent/WO2012091153A2/en not_active Ceased
- 2011-12-26 CA CA2823166A patent/CA2823166C/en active Active
- 2011-12-26 TW TW100148775A patent/TW201304823A/zh unknown
- 2011-12-26 SG SG2013040944A patent/SG190905A1/en unknown
- 2011-12-26 PH PH1/2013/501391A patent/PH12013501391A1/en unknown
- 2011-12-26 MX MX2013007588A patent/MX2013007588A/es not_active Application Discontinuation
- 2011-12-26 UY UY0001033841A patent/UY33841A/es not_active Application Discontinuation
- 2011-12-26 CN CN2011800685821A patent/CN103402500A/zh active Pending
- 2011-12-26 US US13/997,862 patent/US20130273157A1/en not_active Abandoned
- 2011-12-26 AU AU2011350396A patent/AU2011350396A1/en not_active Abandoned
- 2011-12-26 PE PE2013001471A patent/PE20141115A1/es not_active Application Discontinuation
- 2011-12-26 EP EP11811174.9A patent/EP2658530A2/en not_active Withdrawn
- 2011-12-27 AR ARP110104955A patent/AR084610A1/es unknown
-
2013
- 2013-05-24 TN TNP2013000220A patent/TN2013000220A1/fr unknown
- 2013-06-19 CL CL2013001793A patent/CL2013001793A1/es unknown
- 2013-06-21 ZA ZA2013/04617A patent/ZA201304617B/en unknown
- 2013-06-25 EC ECSP13012718 patent/ECSP13012718A/es unknown
- 2013-06-27 CR CR20130327A patent/CR20130327A/es not_active Application Discontinuation
- 2013-06-28 MA MA36063A patent/MA34768B1/fr unknown
- 2013-07-25 CO CO13176405A patent/CO6731132A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012091153A2 (en) | 2012-07-05 |
| CN103402500A (zh) | 2013-11-20 |
| BR112013014875A2 (pt) | 2016-10-18 |
| EA028217B1 (ru) | 2017-10-31 |
| ECSP13012718A (es) | 2013-12-31 |
| TW201304823A (zh) | 2013-02-01 |
| EP2658530A2 (en) | 2013-11-06 |
| EA201390981A1 (ru) | 2014-07-30 |
| PH12013501391A1 (en) | 2013-08-28 |
| WO2012091153A3 (en) | 2012-09-07 |
| CR20130327A (es) | 2013-08-22 |
| US20130273157A1 (en) | 2013-10-17 |
| CL2013001793A1 (es) | 2013-12-06 |
| UY33841A (es) | 2012-07-31 |
| CA2823166A1 (en) | 2012-07-05 |
| TN2013000220A1 (en) | 2014-11-10 |
| PE20141115A1 (es) | 2014-09-12 |
| AU2011350396A1 (en) | 2013-07-11 |
| JP2014501224A (ja) | 2014-01-20 |
| SG190905A1 (en) | 2013-07-31 |
| ZA201304617B (en) | 2014-08-27 |
| CA2823166C (en) | 2019-04-09 |
| SG10201602311XA (en) | 2016-04-28 |
| KR20140007364A (ko) | 2014-01-17 |
| AR084610A1 (es) | 2013-05-29 |
| MA34768B1 (fr) | 2013-12-03 |
| MX2013007588A (es) | 2013-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6731132A2 (es) | Comprimido de desintegración oral | |
| EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
| PE20091620A1 (es) | Preparacion solida de desintegracion oral | |
| PE20211976A1 (es) | Composiciones de liberacion retardada de linaclotida | |
| CL2013003331A1 (es) | Tableta de liberacion inmediata a prueba de alteracion que comprende (i) una matriz, y (ii) una pluralidad de material particulado, que comprende un opiaceo y un polimero de oxido de polietileno de mas de 20.000 g/mol, donde el multiparticulado forma una fase discontinua dentro de la matriz. | |
| EA201400172A1 (ru) | Устойчивая к разрушению таблетка, которая обеспечивает немедленное высвобождение лекарственного средства | |
| PE20131126A1 (es) | Forma de dosificacion resistente a alteracion que comprende un polimero anionico | |
| AR103981A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención | |
| NZ723860A (en) | Pharmaceutical compositions of therapeutically active compounds and their uses | |
| NZ723859A (en) | Pharmaceutical compositions of therapeutically active compounds and their uses | |
| JP2011519967A5 (https=) | ||
| RU2012136839A (ru) | Композиции для ухода за полостью рта и устранения неприятного запаха | |
| AR102228A1 (es) | Una formulación de metformina de liberación sostenida y un método de preparación de la misma | |
| UA117260C2 (uk) | Лікарський препарат з відстроченим вивільненням | |
| CO6640256A2 (es) | Tableta enterica | |
| TR201010683A1 (tr) | Vildagliptin formülasyonları. | |
| JP2013529637A5 (https=) | ||
| IL308650B2 (en) | Gastro-resistant controlled release oral dosage forms | |
| GT201400094A (es) | Formulación de liberación inmediata de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)-fenil]-benzamida | |
| MX2015010449A (es) | Composicion farmaceutica multiparticulada que comprende una multitud de dos clases de granulos. | |
| RU2008130892A (ru) | Твердое лекарственное средство с контролируемым высвобождением | |
| RU2015140119A (ru) | Таблетка, покрытая кишечнорастворимым покрытием | |
| EA201591787A1 (ru) | Таблетки совапревира | |
| AR111786A1 (es) | Composiciones de gemcabeno y su uso | |
| CA2797809A1 (en) | Enteric tablet |